Article Text
Statistics from Altmetric.com
QUESTION: In men with node positive prostate cancer, is survival prolonged by starting anti-androgen treatment immediately after surgery rather than delaying it until the appearance of disease progression?
Design
Randomised {allocation concealed*}†, unblinded,* controlled trial with median 7.1 years follow up.
Setting
6 US university centres.
Patients
98 men (median age 66 y) who had clinically localised prostate cancer (≤ stage T2), had had radical prostatectomy and bilateral pelvic lymphadenectomy within the previous 12 weeks, and had histologically confirmed nodal metastases.
Intervention
Patients were allocated to anti-androgen treatment with either goserelin, 3.6 mg subcutaneously every 28 days, or bilateral orchiectomy (n=47) or to be followed until evidence existed of disease progression other than newly detectable or rising levels of prostate specific …
Footnotes
-
Sources of funding: National Institutes of Health and Department of Health and Human Services.
-
For correspondence: Dr E M Messing, University of Rochester, Department of Urology, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA. Fax +1 716 442 8350.
↵† Information provided by author.